It’s been nearly 10 years since the CDC first recommended immunization against human papillomavirus (HPV), the disease known to cause many types of gynecological and reproductive cancers. During that time, numerous studies have supported the vaccine’s efficiency. Yet through a decade of endorsements and advancements, the HPV vaccine continues to fall below target rates.
Human papillomavirus (HPV) is the most common sexually transmitted virus in the United States—so common that nearly every sexually active person will acquire it at some point in his or her life. When not cleared by one’s immune system, certain strains of the virus are linked to serious health issues including genital warts and numerous types of cancer.